{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T03:58:32Z","timestamp":1779249512232,"version":"3.51.4"},"reference-count":61,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parasitology International"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.parint.2017.08.007","type":"journal-article","created":{"date-parts":[[2017,8,21]],"date-time":"2017-08-21T07:16:50Z","timestamp":1503299810000},"page":"735-747","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["The effect of lopinavir\/ritonavir and lopinavir\/ritonavir loaded PLGA nanoparticles on experimental toxoplasmosis"],"prefix":"10.1016","volume":"66","author":[{"given":"Iman Fathy","family":"Abou-El-Naga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eman Dorry","family":"El Kerdany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rasha Fadly","family":"Mady","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thanaa Ibrahim","family":"Shalaby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enas Mohammed","family":"Zaytoun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.parint.2017.08.007_bb0005","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.ijpara.2009.02.004","article-title":"Toxoplasmosis: a history of clinical observations","volume":"39","author":"Weiss","year":"2009","journal-title":"Int. J. Parasitol."},{"issue":"3","key":"10.1016\/j.parint.2017.08.007_bb0010","doi-asserted-by":"crossref","first-page":"e90203","DOI":"10.1371\/journal.pone.0090203","article-title":"Toxoplasmosis- a global threat. Correlation of latent toxoplasmosis with specific disease burden in a set of 88 countries","volume":"9","author":"Flegr","year":"2014","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.parint.2017.08.007_bb0015","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.2217\/fmb.09.89","article-title":"Toxoplasma gondii infection and cerebral toxoplasmosis in HIV- infected patients","volume":"4","author":"Pereira-Chioccola","year":"2009","journal-title":"Future Microbiol."},{"issue":"1\u20132","key":"10.1016\/j.parint.2017.08.007_bb0020","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.vetpar.2007.07.003","article-title":"Toxoplasma gondii and ovine toxoplasmosis: new aspects of an old story","volume":"149","author":"Buxto","year":"2007","journal-title":"Vet. Parasitol."},{"issue":"5","key":"10.1016\/j.parint.2017.08.007_bb0025","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1084\/jem.136.5.1173","article-title":"The interaction between Toxoplasma gondii and mammalian cells. II. The absence of lysosomal fusion with phagocytic vacuoles containing living parasites","volume":"136","author":"Jones","year":"1972","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.parint.2017.08.007_bb0030","doi-asserted-by":"crossref","first-page":"D391","DOI":"10.2741\/A521","article-title":"The development and biology of bradyzoites of Toxoplasma gondii","volume":"5","author":"Weiss","year":"2000","journal-title":"Front. Biosci."},{"key":"10.1016\/j.parint.2017.08.007_bb0035","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/nrmicro1800","article-title":"Kiss and spit: the dual roles of Toxoplasma rhoptries","volume":"6","author":"Boothroyd","year":"2008","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.parint.2017.08.007_bb0040","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nmeth.1438","article-title":"Toxoplasma secreting are recombinase for analysis of host-parasite interactions","volume":"7","author":"Koshy","year":"2010","journal-title":"Nat. Methods"},{"key":"10.1016\/j.parint.2017.08.007_bb0045","first-page":"4","article-title":"An aspartyl protease defines a novel pathway for export of Toxoplasma proteins into the host cell","volume":"18","author":"Coffey","year":"2015","journal-title":"elife"},{"key":"10.1016\/j.parint.2017.08.007_bb0050","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.biopha.2016.05.041","article-title":"Human toxoplasmosis-Searching for novel chemotherapeutics","volume":"82","author":"Antczak","year":"2016","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.parint.2017.08.007_bb0055","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.pt.2004.11.003","article-title":"The impact of HIV-protease inhibitors on opportunistic parasites","volume":"21","author":"Pozio","year":"2005","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.parint.2017.08.007_bb0060","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.bjid.2012.10.030","article-title":"AIDS-related cerebral toxoplasmosis in Sao Paulo State, Brazil: marked improvements in the highly active antiretroviral therapy-era but the challenges continue","volume":"17","author":"Vidal","year":"2013","journal-title":"Braz. J. Infect. Dis."},{"key":"10.1016\/j.parint.2017.08.007_bb0065","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/713609213","article-title":"Aspartic peptidase inhibitors: implications in drug development","volume":"38","author":"Dash","year":"2003","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"10.1016\/j.parint.2017.08.007_bb0070","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1056\/NEJM199804303381808","article-title":"HIV-protease inhibitors","volume":"338","author":"Flexner","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.parint.2017.08.007_bb0075","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1128\/AAC.44.9.2575-2577.2000","article-title":"Anti-Toxoplasma activities drugs and interactions with Pyrimethamine and Sulfadiazine in vitro","volume":"44","author":"Derouin","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.parint.2017.08.007_bb0080","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1086\/314871","article-title":"In vitro and in vivo anticandidal activity of human immune deficiency virus protease inhibitors","volume":"180","author":"Cassone","year":"1999","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.parint.2017.08.007_bb0085","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1086\/315437","article-title":"In vitro activity of human immunodeficiency virus protease inhibitors against Pneumocystis carinii","volume":"181","author":"Atzori","year":"2000","journal-title":"J. Infect. Dis."},{"issue":"12","key":"10.1016\/j.parint.2017.08.007_bb0090","doi-asserted-by":"crossref","first-page":"e113957","DOI":"10.1371\/journal.pone.0113957","article-title":"Decoding the anti-Trypanosoma cruzi action of HIV peptidase inhibitors using epimastigotes as a model","volume":"9","author":"Sangenito","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.parint.2017.08.007_bb0095","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.ijantimicag.2016.06.024","article-title":"HIV aspartic peptidase inhibitors are effective drugs against the trypomastigote form of the human pathogen Trypanosoma cruzi","volume":"48","author":"Sangenito","year":"2016","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.parint.2017.08.007_bb0100","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.molbiopara.2005.05.015","article-title":"Characterization of plasmepsin V, a membrane-bound aspartic protease homolog in the endoplasmic reticulum of Plasmodium falciparum","volume":"143","author":"Klemba","year":"2005","journal-title":"Mol. Biochem. Parasitol."},{"key":"10.1016\/j.parint.2017.08.007_bb0105","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1128\/AAC.49.7.2983-2985.2005","article-title":"Antimalarial activity of human immune defiency Virus Type 1","volume":"49","author":"Parikh","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.parint.2017.08.007_bb0110","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1111\/j.1600-0854.2007.00589.x","article-title":"A family of aspartic proteases and a novel, dynamic and cell-cycle-dependent protease localization in the secretory pathway of Toxoplasma gondii","volume":"8","author":"Shea","year":"2007","journal-title":"Traffic"},{"key":"10.1016\/j.parint.2017.08.007_bb0115","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ijantimicag.2008.10.010","article-title":"Anti-HIV drugs 25 compounds approved within 25 years after the discovery of HIV","volume":"33","author":"De Clercq","year":"2009","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"5","key":"10.1016\/j.parint.2017.08.007_bb0120","first-page":"1023","article-title":"Lopinavir\/ritonavir in the treatment of HIV-1 infection","volume":"4","author":"Chandwani","year":"2008","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.parint.2017.08.007_bb0125","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/01.wco.0000236614.51592.ca","article-title":"Influence of highly active antiretroviral therapy on persistence of HIV in the central nervous system","volume":"19","author":"Nath","year":"2006","journal-title":"Curr. Opin. Neural."},{"issue":"5","key":"10.1016\/j.parint.2017.08.007_bb0130","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1097\/01.ftd.0000245681.12092.d6","article-title":"A retrospective TDM database analysis of interpatient variability in the pharmacokinetics of lopinavir in HIV-infected adults","volume":"28","author":"Van der Leur","year":"2006","journal-title":"Ther. Drug Monit."},{"issue":"9","key":"10.1016\/j.parint.2017.08.007_bb0135","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1002\/jps.24492","article-title":"Enhanced boosting of oral absorption of lopinavir through electrospray coencapsulation with ritonavir","volume":"104","author":"Sakuma","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.parint.2017.08.007_bb0140","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1517\/14656560902980202","article-title":"HIV protease inhibitors: recent clinical trials and recommendations on use","volume":"10","author":"Fernandez Montero","year":"2009","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.parint.2017.08.007_bb0145","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/1471-2334-9-198","article-title":"Combination antiretroviral drugs in PLGA nanoparticle for HIV-1","volume":"9","author":"Destache","year":"2009","journal-title":"BMC Infect. Dis."},{"issue":"5","key":"10.1016\/j.parint.2017.08.007_bb0150","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1021\/nn5066793","article-title":"pH-responsive poly (d,l-lactic-co-glycolic acid) nanoparticles with rapid antigen release behavior promote-immune response","volume":"9","author":"Liu","year":"2015","journal-title":"ACS Nano"},{"issue":"2","key":"10.1016\/j.parint.2017.08.007_bb0155","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1128\/AAC.35.2.293","article-title":"Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii","volume":"35","author":"Araujo","year":"1991","journal-title":"Antimicrob. Agents Chemother."},{"issue":"8","key":"10.1016\/j.parint.2017.08.007_bb0160","doi-asserted-by":"crossref","first-page":"769","DOI":"10.2165\/00003495-200363080-00004","article-title":"Lopinavir\/ritonavir: a review of its use in the management of HIV infection","volume":"63","author":"Cvetkovic","year":"2003","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.parint.2017.08.007_bb0165","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1006\/expr.1998.4267","article-title":"Encephalitozoon intestinalis: humoral responses in interferon-gamma receptor knockout mice infected with a microsporidium pathogenic in AIDS patients","volume":"89","author":"El Fakhry","year":"1998","journal-title":"Exp. Parasitol."},{"key":"10.1016\/j.parint.2017.08.007_bb0170","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0924-8579(99)00073-4","article-title":"Evaluation of trimethoprim and sulphamethoxazole as monotherapy or in combination in the management of toxoplasmosis in murine models","volume":"13","author":"Dumas","year":"1999","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"2","key":"10.1016\/j.parint.2017.08.007_bb0175","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.foodhyd.2011.10.015","article-title":"Impact of chemical composition of xanthan and acacia gums on the emulsification and stability of oilin-water emulsions","volume":"27","author":"Desplanques","year":"2012","journal-title":"J. Food Hydr."},{"issue":"3","key":"10.1016\/j.parint.2017.08.007_bb0180","first-page":"645","article-title":"Natural Toxoplasma infection sought in the Indian grey mongoose (H. Edwardsi, Greffroy, 1818) trapped in the eastern region., Saudi Arabia","volume":"26","author":"Al Dakhil","year":"1996","journal-title":"J. Egypt. Soc. Parasitol."},{"key":"10.1016\/j.parint.2017.08.007_bb0185","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.exppara.2014.12.007","article-title":"Triclosan and triclosan-loaded liposomal nanoparticles in the treatment of acute experimental toxoplasmosis","volume":"149","author":"El-Zawawy","year":"2015","journal-title":"Exp. Parasitol."},{"issue":"3","key":"10.1016\/j.parint.2017.08.007_bb0190","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/infdis\/121.3.339","article-title":"Scanning-beam electron microscopy of selected microorganisms","volume":"121","author":"Klainer","year":"1970","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.parint.2017.08.007_bb0195","series-title":"A Simple Guide to IBM SPSS Statistics for Version 20.0","author":"Kirkpatrick","year":"2013"},{"key":"10.1016\/j.parint.2017.08.007_bb0200","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/COH.0b013e32835b7f94","article-title":"Emerging HIV-1 drug resistance after roll-out of antiretroviral therapy in sub-Saharan Africa","volume":"8","author":"Hamers","year":"2013","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.parint.2017.08.007_bb0205","series-title":"Current Clinical Topics in Infectious Disease","first-page":"154","article-title":"Antiretroviral chemotherapy","author":"Saag","year":"1998"},{"key":"10.1016\/j.parint.2017.08.007_bb0210","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1128\/AAC.50.2.639-648.2006","article-title":"Potencies of human immunodeficiency virus protease inhibitors in vitro against Plasmodium falciparum and in vivo against murine malaria","volume":"50","author":"Andrews","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.parint.2017.08.007_bb0215","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.exppara.2006.10.006","article-title":"Leishmania mexicana: Identification and characterization of an aspartyl proteinase activity","volume":"116","author":"Valdivieso","year":"2007","journal-title":"Exp. Parasitol."},{"issue":"3","key":"10.1016\/j.parint.2017.08.007_bb0220","doi-asserted-by":"crossref","first-page":"e4918","DOI":"10.1371\/journal.pone.0004918","article-title":"HIV aspartyl peptidase inhibitors interfere with cellular proliferation, ultrastructure and macrophage infection of Leishmania amazonensis","volume":"4","author":"Santos","year":"2009","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.parint.2017.08.007_bb0225","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1128\/AAC.34.5.775","article-title":"In vitro and in vivo effects of doxycycline onToxoplasma gondii","volume":"34","author":"Chang","year":"1990","journal-title":"Antimicrob. Agents Chemother."},{"issue":"11","key":"10.1016\/j.parint.2017.08.007_bb0230","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1128\/AAC.37.11.2371","article-title":"In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii","volume":"37","author":"Romand","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.parint.2017.08.007_bb0235","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1590\/S0036-46652013000100012","article-title":"Antiretroviral activity of protease inhibitors against Toxoplasma gondii","volume":"55","author":"Monzote","year":"2013","journal-title":"Rev. Inst. Med. Trop. Sao Paulo"},{"issue":"10","key":"10.1016\/j.parint.2017.08.007_bb0240","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1111\/j.1462-5822.2009.01357.x","article-title":"New roles for perforins and proteases in apicomplexan egress","volume":"11","author":"Roiko","year":"2009","journal-title":"Cell. Microbiol."},{"key":"10.1016\/j.parint.2017.08.007_bb0245","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1128\/MMBR.64.3.607-623.2000","article-title":"Lytic cycle of Toxoplasma gondii","volume":"64","author":"Black","year":"2000","journal-title":"Microbiol. Mol. Biol. Rev."},{"issue":"10","key":"10.1016\/j.parint.2017.08.007_bb0250","doi-asserted-by":"crossref","first-page":"e1005211","DOI":"10.1371\/journal.ppat.1005211","article-title":"Fundamental roles of the golgi-associated Toxoplasma aspartyl protease, ASP5, at the host-parasite interface","volume":"11","author":"Hammoudi","year":"2015","journal-title":"PLoS Pathog."},{"issue":"1","key":"10.1016\/j.parint.2017.08.007_bb0255","first-page":"185","article-title":"Effect of artesunate on Toxoplasma gondii: in vitro and in vivo studies","volume":"38","author":"El Zawawy","year":"2008","journal-title":"J. Egypt. Soc. Parasitol."},{"key":"10.1016\/j.parint.2017.08.007_bb0260","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/cdd.2008.150","article-title":"Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009","volume":"16","author":"Kroemer","year":"2009","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.parint.2017.08.007_bb0265","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1126\/science.1099993","article-title":"Autophagy in health and disease: a double-edged sword","volume":"306","author":"Shintani","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.parint.2017.08.007_bb0270","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1007\/s00436-014-3853-5","article-title":"Autophagy activated by Toxoplasma gondii infection in turn facilitates Toxoplasma gondii proliferation","volume":"113","author":"Gao","year":"2014","journal-title":"Parasitol. Res."},{"issue":"5","key":"10.1016\/j.parint.2017.08.007_bb0275","doi-asserted-by":"crossref","first-page":"e01157","DOI":"10.1128\/mBio.01157-15","article-title":"A noncanonical autophagy pathway restricts Toxoplasma gondii growth in a strain-specific manner in IFN-\u03b3-activated human cells","volume":"6","author":"Selleck","year":"2015","journal-title":"MBio"},{"issue":"7","key":"10.1016\/j.parint.2017.08.007_bb0280","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1007\/s00436-016-5040-3","article-title":"The morphologicalanalysis of autophagy in primary skeletal muscle cells infected with Toxoplasma gondii","volume":"115","author":"Souto","year":"2016","journal-title":"Parasitol. Res."},{"key":"10.1016\/j.parint.2017.08.007_bb0285","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.cell.2006.01.056","article-title":"Toxoplasma gondii sequesters lysosomes from mammalian hosts in the vacuolar space","volume":"125","author":"Coppens","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.parint.2017.08.007_bb0290","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1126\/science.2200126","article-title":"Toxoplasma gondii: fusion competence of parasitophorous vacuoles in Fc receptor transfected fibroblasts","volume":"249","author":"Joiner","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.parint.2017.08.007_bb0295","doi-asserted-by":"crossref","first-page":"4452","DOI":"10.4049\/jimmunol.159.9.4452","article-title":"Intracellular fate of vacuoles containing Toxoplasma gondii is determined at the time of formation and depends on the mechanisms of entry","volume":"159","author":"Mordue","year":"1997","journal-title":"J. Immunol."},{"key":"10.1016\/j.parint.2017.08.007_bb0300","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1242\/jcs.108.4.1669","article-title":"Regulated secretion of multi-lamellar vesicles leads to formation of a tubule vesicular network in host-cell vacuoles occupied by Toxoplasma gondii","volume":"108","author":"Sibley","year":"1995","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.parint.2017.08.007_bb0305","first-page":"114","article-title":"Sequential protein secretion from three distinct organelles of Toxoplasma gondii accompanies invasion of human fibroblasts","volume":"73","author":"Carruthers","year":"1997","journal-title":"Eur. J. Cell Biol."}],"container-title":["Parasitology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S138357691730301X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S138357691730301X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T04:50:48Z","timestamp":1692939048000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S138357691730301X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":61,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S138357691730301X"],"URL":"https:\/\/doi.org\/10.1016\/j.parint.2017.08.007","relation":{},"ISSN":["1383-5769"],"issn-type":[{"value":"1383-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of lopinavir\/ritonavir and lopinavir\/ritonavir loaded PLGA nanoparticles on experimental toxoplasmosis","name":"articletitle","label":"Article Title"},{"value":"Parasitology International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parint.2017.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}